News >

Tucatinib Active in Heavily Pretreated HER2+ Breast Cancer

Jason Harris
Published: Tuesday, Jun 12, 2018

Rashmi K. Murthy, MD, MBE

Rashmi K. Murthy, MD, MBE
Tucatinib used in combination with capecitabine, trastuzumab (Herceptin), or both agents showed promising antitumor activity in heavily pretreated women with HER2-positive breast cancer with or without brain metastases, according to findings published in The Lancet Oncology.1
... to read the full story
To Read the Full Story



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x